Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to investigate the superiority of KPS-0373 to placebo, and evaluate the safety of KPS-0373 in SCD patients.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT02889302
Study type Interventional
Source Kissei Pharmaceutical Co., Ltd.
Contact
Status Completed
Phase Phase 3
Start date November 15, 2016
Completion date March 2018

See also
  Status Clinical Trial Phase
Completed NCT01970098 - A Confirmatory Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD) Phase 3
Completed NCT04107740 - C-Trelin Orally Disintegrated(OD) Tablet 5mg in Ataxia Due to Spinocerebellar Degeneration Phase 4
Completed NCT01970111 - An Extension Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD) Phase 3
Completed NCT01970137 - A 24-week Open-label Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD) Phase 3
Completed NCT00863538 - Phase II Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD) Phase 2
Completed NCT01970124 - A Long-Term Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD) Phase 3
Completed NCT01004016 - A Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD) Phase 2